Clinical trial
Evaluation of the Safety and Performance of the Very High Power-Short Duration QDOT Strategy in Patients Referred for Atrial Fibrillation Ablation.
NCT04592497 is registered in ClinicalTrials.gov with Tel-Aviv Sourasky Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Safety and Performance of the Very High Power-Short Duration QDOT Strategy in Patients Referred for Atrial Fibrillation Ablation.
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 15, 2020
- Completion date
- October 1, 2022
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.